Literature DB >> 6617931

Free and total carnitine in human serum after oral ingestion of L-carnitine.

A C Bach, H Schirardin, M O Sihr, D Storck.   

Abstract

Twelve students with in apparent good health and fasting since the previous evening ingested 2 g of L-carnitine on one day and a placebo on another day in a single-blind trial. Six blood samples were taken during the 24 h following the ingestion. Their blood carnitine levels increased (the free form by 81%, and the total by 57%) to a maximum at about 3.5 h and then slowly decreased. Twenty-four hours after ingestion, blood carnitine concentrations had still not returned to their initial levels. In the time interval where the decay curve approximated a single exponential, the half-life of the carnitine appeared to be of the order of 15 h. During the 24 h after the administration of the 2 g of L-carnitine, 7% +/- 1% of it was eliminated in the urine. This work suggest that the daily administration during a long period, of 2 g of L-carnitine guarantee in a healthy subject blood carnitine concentrations superior to the normal levels. Its remains to determine if the dose is sufficient in the case where L-carnitine is given to ameliorate a primary or secondary lack of carnitine, or to lower a high level of lipids in blood.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617931

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  9 in total

1.  Carnitine administration as a tool of modify energy metabolism during exercise.

Authors:  E Hultman; G Cederblad; P Harper
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

Review 2.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

3.  Screening for drugs potentially interfering with MCT8-mediated T3 transport in vitro identifies dexamethasone and some commonly used drugs as inhibitors of MCT8 activity.

Authors:  C Di Cosmo; G De Marco; P Agretti; E Ferrarini; A Dimida; P Falcetta; S Benvenga; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2021-11-30       Impact factor: 4.256

Review 4.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

5.  Pharmacokinetics of intravenous and oral bolus doses of L-carnitine in healthy subjects.

Authors:  P Harper; C E Elwin; G Cederblad
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

7.  Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.

Authors:  W A Gahl; I Bernardini; M Dalakas; W B Rizzo; G S Harper; J M Hoeg; O Hurko; J Bernar
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

8.  Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects.

Authors:  P Harper; C E Elwin; G Cederblad
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.

Authors:  F Graziano; R Bisonni; V Catalano; R Silva; S Rovidati; E Mencarini; B Ferraro; F Canestrari; A M Baldelli; A De Gaetano; P Giordani; E Testa; V Lai
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.